drugset
drugset / Trial / NCT06229912

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

NCT06229912 ↗

Phase 2 Recruiting 40 enrolled M.D. Anderson Cancer Center Syndax Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

Timeline

Start
2024-06-04
Primary completion
2026-12-01
Completion
2028-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Revumenib Small molecule — Oral

Indications

leukemia